Top 50 Pharmaceutical Companies 2014

Who are the top pharmaceutical companies in the world and what are they worth in 2014? The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with …

Download: The value of non-commercial engagement

At DigiPharm 2013, Shona Davies, Global Communications & Programme Leader Associate Director, Merck gave a presentation on “The value of non-commercial engagement” Download the presentation to learn: What is the business value of a non-commercial engagement Relationships: Customer Engagement Strategies & Permission Defining RoI for non-promotional services What kind of benefit could there possibly be? Download presentation To find out more …

big data in pharma

Big Data Analytics Companies: Competitors or Collaborators?

  An industry survey of 1,600 pharmacy professional, which reveals some very interesting trends in the way the industry perceives its future. The 971 who responded included managers (39 percent), directors (30 percent), consultants (10 percent), CEOs (9 percent), and sales reps (9 percent). Perhaps one of the most interesting revelations of this survey is that 59 percent of them …

Download: Changing commercial model and implications on marketing and sales

At last year’s DigiPharm conference, Ragnar Gåseby, Executive Director, Global Leader of MCM COE, gave an in-depth presentation on the “Changing commercial model and implications on marketing and sales” Gåseby highlights key trends: Reduced physician influence on Rx Austerity measures and price pressure Changes in communication channel preferences The increasing information flow The educated patient And their implications: How to …

Download Presentation: Facilitating External Collaborations through Regional Licensing & Acquisitions

At the last BioPharma Asia in 2013, Dr Phil Kearney of Merck Sharp and Dohme gave the following presentation entitled: Facilitating External Collaborations through Regional Licensing & Acquisitions. Click here to download this presentation. The presentation covered: Merck’s strategy changes to strengthen licensing & Acquisition Pharma’s current challenges/opportunities Overview of Merck’s licensing processes and partnering opportunities MINT (Merck Initiative for …

FDA panel backs Merck insomnia drug, but warns of safety concerns

An FDA panel might have given its backing to Merck's insomnia drug suvorexant, but this may not signal the end for the pharmaceutical giant's sleepless nights. The US Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee has recommended Merck's suvorexant when given in low dosages, but the panel rejected the drug in higher doses due to …

Merck and Pfizer collaborate on new diabetes drug

An unlikely partnership? Perhaps, but Merck (MSD) and Pfizer have joined forces to develop and commercialize a drug for type 2 diabetes mellitus, according to a report by Reuters. The drug, ertugliflozin, is an oral sodium glucose cotransporter (SGLT2) inhibitor, and is nearing Phase III trials – behind J&J's Invokana (canagliflozin) which was recently approved in the US. Ertugliflozin will …

Indian court denies Merck interim relief in Glenmark diabetes patent case

After the news that Novartis failed to secure an Indian patent for Glivec, the patenting woes of Western pharma in India seem to continue as Merck are denied interim relief in a patent case against Indian firm Glenmark Pharmaceuticals, reports the Economic Times. According to the Economic Times, the Delhi High Court has dismissed Merck's interim application that Glenmark Pharmaceuticals …